InMed Pharmaceuticals (INM) 10% Owner LLC Buys $1.3K of Stock
ADAR1 Capital Management has bought more shares of InMed Pharmaceuticals, totaling 984 shares at $1.32 each.
Reviewed by automated data checks against the source filing. How we make and check alerts
ADAR1 Capital Management, LLC, 10% Owner at InMed Pharmaceuticals Inc. ($INM), bought 984 shares at an average price of $1.32, worth about $1,300.75, on October 15, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $INM is down 0.8% to date (from the $1.33 close on Oct 15, 2026).
INM
InMed Pharmaceuticals Inc.
Key Points
- On October 15, 2026, ADAR1 Capital Management purchased 984 shares of InMed Pharmaceuticals at $1.32 each, totaling about $1,300.75.
- The stock recently traded around $1.32, which is 4.4% below its 50-day moving average of $1.38 but 11.4% above its 200-day average of $1.18.
- ADAR1 Capital Management now holds 42,920 shares of InMed Pharmaceuticals, valued at approximately $57,080.
Get $INM trade alerts by text
We text you when insiders, Congress or big funds trade $INM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated InMed Pharmaceuticals Inc. alert may contain errors. Disclosures
ADAR1 Capital Management, LLC bought 984 shares of InMed Pharmaceuticals Inc. (NasdaqCM: INM) on October 15, 2026, at a price of $1.32 per share. This purchase is valued at about $1,300.75 and increases ADAR1's total holdings in the company.
ADAR1 Capital Management, LLC vs. the S&P 500
Hypothetical returns from ADAR1 Capital Management, LLC's disclosed trades, not real profit or advice. How we model this.
Inside ADAR1 Capital Management's Trade
ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals, added 984 shares to its position. This brings its total to 42,920 shares. The recent purchase is part of a series of transactions by ADAR1, which has been steadily increasing its stake in the company.
Other Institutional Activity in InMed Pharmaceuticals
Alongside ADAR1, other funds have also shown interest in InMed Pharmaceuticals. Vivo Capital, LLC holds 798,377 shares valued at about $1,053,857 after adding 399,188 shares. Squadron Capital Management LLC has 325,000 shares worth approximately $429,000 after boosting its stake by 162,500 shares. Ikarian Capital, LLC increased its holdings to 245,025 shares, valued at $323,433, with a recent gain of 122,512 shares. Additionally, Ursa Fund Management, LLC holds 125,800 shares worth about $166,056 after increasing its position by 62,900 shares.
InMed Pharmaceuticals Inc. Stock Down 0.8%
As of October 16, 2026, InMed Pharmaceuticals' stock trades around $1.32. This is 4.4% below its 50-day moving average of $1.38 and 11.4% above its 200-day average of $1.18. The stock is currently 43.3% below its 52-week high of $2.33, but importantly, it is 129.6% above its 52-week low of $0.57.
Recent Earnings
InMed Pharmaceuticals has not reported any earnings yet, but it is scheduled to announce its next earnings on November 5, 2026. Investors will be looking for updates on its financial health and product development.
Insider Buying and Selling at InMed Pharmaceuticals Inc.
Recently, ADAR1 Capital Management has been active in acquiring shares. On October 14, 2026, it bought 8,021 shares at $1.33 each, totaling about $10,668. Prior to that, it purchased 10,903 shares on October 8, 2026, also at $1.33, valued at around $14,484. These transactions show a consistent interest from ADAR1 in increasing its stake in InMed Pharmaceuticals.
About InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a drug development company based in Vancouver, BC. It focuses on cannabinoid-based pharmaceuticals, including treatments for Alzheimer's disease and age-related macular degeneration. The company’s innovative approach positions it in the growing healthcare sector, particularly in specialty drug manufacturing.
Bottom Line
Investors should keep an eye on InMed Pharmaceuticals as it prepares for its next earnings report on November 5, 2026. The continued buying by ADAR1 Capital Management suggests confidence in the company's future prospects.
Related Filing Alerts
Source: ADAR1 Capital Management, LLC's Form 4 filing on $INM (Oct 15, 2026). Find the original filing: INM Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts